<DOC>
	<DOCNO>NCT00772954</DOCNO>
	<brief_summary>This Phase I , randomize , placebo-controlled , double-blinded , dose range study ass safety , tolerability , immunogenicity 2 dose level C. difficile vaccine . Population : healthy male female adult , 18 55 year old .</brief_summary>
	<brief_title>Phase I Randomized , Placebo-Controlled , Double-Blind , Dose Ranging Study , Safety , Tolerability Immunogenicity</brief_title>
	<detailed_description>This Phase I , randomize , placebo-controlled , double-blinded , dose range study design assess safety , tolerability , immunogenicity C. difficile vaccine . The study conduct healthy male female adult , 18 55 year old . Subjects randomly assign Day 0 receive one two dos C. difficile vaccine ( 50 100 mcg ) placebo ( vehicle control contain alum ) .</detailed_description>
	<mesh_term>Diarrhea</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Adult male female , 18 55 year good general health Evidence current C. difficile infection , determine positive stool C. difficile cytotoxin assay screen Evidence previous antibioticassociated diarrhea cause etiology include C. difficile require medical intervention medication Active inactive irritable bowel disease , chronic abdominal pain , chronic diarrhea etiology , inflammatory bowel disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Clostridium difficile diarrhea</keyword>
	<keyword>Clostridium difficile toxoid vaccine</keyword>
</DOC>